Goodwin Advised Moderna on Strategic Collaboration with Recordati for mRNA-3927 Therapeutic

Goodwin Advised Moderna on Strategic Collaboration with Recordati for mRNA-3927 Therapeutic

Goodwin advised Moderna, Inc. (“Moderna”) on a strategic collaboration with Recordati to advance Moderna’s investigational propionic acidemia (PA) therapeutic, mRNA-3927, through the final stages of clinical development and, upon approval, global commercialization. Under the terms of the agreement, Moderna will receive an upfront payment of $50 million and up to an additional $110 million in development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales. Recordati, based in Milan, Italy, will lead commercialization while Moderna continues to lead clinical development.

Under the terms of the agreement, Moderna will receive an upfront payment of $50 million and up to an additional $110 million in near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales.

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.

The Goodwin team was led by Felipe Heiderich (Partner), Stuart Cable (Vice Chair/ Global Head/ M&A), Kingsley Taft (Partner/ Co-Chair/ Life Sciences), and Austin Church (Associate/ Life Sciences), Dan Karelitz (Partner/ Tax), Susan Lee (Partner/ FDA), Paul Jin (Partner) and Kevin Walsh (Counsel/ Antitrust), with invaluable support from Sarah Solomon (Partner) and Frank Ruofan Qin (Associate)

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.